A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Phase of Trial: Phase II
Latest Information Update: 18 Jun 2018
At a glance
- Drugs Cridanimod (Primary) ; Megestrol
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors Xenetic Biosciences
- 11 Jan 2018 Planned end date changed from 30 Nov 2020 to 31 Jan 2021.
- 11 Jan 2018 Planned primary completion date changed from 30 Nov 2020 to 31 Jan 2021.
- 15 Nov 2017 According to a Xenetic Biosciences media release, dosing has commenced in this trial.